Study of GI-108 for advanced solid tumors
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests a new drug called GI-108, which is designed to help your immune system fight cancer. It is for people with advanced or metastatic solid tumors that have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old (or 19 in some countries).
- Your cancer must be measurable on scans (by RECIST criteria).
- You need to be in good enough health to carry out daily activities (ECOG score 0 or 1).
- Any side effects from past treatments should have mostly resolved (except hair loss or mild nerve tingling).
- If you have HIV, it must be well-controlled with medication.
- You cannot have untreated or active brain metastases, another active cancer, or certain infections (like active hepatitis B or C, or tuberculosis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests GI-101 in people with advanced solid cancers. It may be given alone or combined with pembrolizumab or lenvatinib to see how safe it is and whether it can shrink tumors.
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
This early-stage trial tests a new cancer drug called ICP-B208 in people with advanced solid tumors (like stomach, colon, or other cancers) that have spread or cannot be removed surgically and have not responded to previous treatments. The study aims to find the right dose and see how well the drug works.
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.